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Abstract: BACKGROUND AND PURPOSE The aim of this study was to evaluate and independently
validate SAA (serum amyloid A)-a recently discovered blood biomarker-to predict poststroke infections.
METHODS The derivation cohort (A) was composed of 283 acute ischemic stroke patients and the inde-
pendent validation cohort (B), of 367 patients. The primary outcome measure was any stroke-associated
infection, defined by the criteria of the US Centers for Disease Control and Prevention, occurring during
hospitalization. To determine the association of SAA levels on admission with the development of in-
fections, logistic regression models were calculated. The discriminatory ability of SAA was assessed, by
calculating the area under the receiver operating characteristic curve. RESULTS After adjusting for all
predictors that were significantly associated with any infection in the univariate analysis, SAA remained
an independent predictor in study A (adjusted odds ratio, 1.44 [95% CI, 1.16-1.79]; P=0.001) and in
study B (adjusted odds ratio, 1.52 [1.05-2.22]; P=0.028). Adding SAA to the best regression model
without the biomarker, the discriminatory accuracy improved from 0.76 (0.69-0.83) to 0.79 (0.72-0.86;
P<0.001; likelihood ratio test) in study A. These results were externally validated in study B with an
improvement in the area under the receiver operating characteristic curve, from 0.75 (0.70-0.81) to 0.76
(0.71-0.82; P<0.038). CONCLUSIONS Among patients with ischemic stroke, blood SAA measured on
admission is a novel independent predictor of infection after stroke. SAA improved the discrimination
between patients who developed an infection compared with those who did not in both derivation and
validation cohorts. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00390962.
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Background and Purpose: The aim of this study was to evaluate and independently validate 
SAA (serum amyloid A)—a recently discovered blood biomarker—to predict poststroke 
infections. 
Methods: The derivation cohort (A) was composed of 283 acute ischemic stroke patients 
and the independent validation cohort (B), of 367 patients. The primary outcome measure 
was any stroke-associated infection, defined by the criteria of the US Centers for Disease 
Control and Prevention, occurring during hospitalization. To determine the association of 
SAA levels on admission with the development of infections, logistic regression models 
were calculated. The discriminatory ability of SAA was assessed, by calculating the area 
under the receiver operating characteristic curve. 
Results: After adjusting for all predictors that were significantly associated with any infection 
in the univariate analysis, SAA remained an independent predictor in study A (adjusted odds 
ratio, 1.44 [95% CI, 1.16–1.79]; P=0.001) and in study B (adjusted odds ratio, 1.52 [1.05–
2.22]; P=0.028). Adding SAA to the best regression model without the biomarker, the 
discriminatory accuracy improved from 0.76 (0.69–0.83) to 0.79 (0.72–0.86; P<0.001; 
likelihood ratio test) in study A. These results were externally validated in study B with an 
improvement in the area under the receiver operating characteristic curve, from 0.75 (0.70–
0.81) to 0.76 (0.71–0.82; P<0.038). 
Conclusion: Among patients with ischemic stroke, blood SAA measured on admission is a 
novel independent predictor of infection after stroke. SAA improved the discrimination 
between patients who developed an infection compared with those who did not in both 
derivation and validation cohorts. 
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Nosocomial infections are the most common complication after ischemic stroke (IS) with 
frequencies of 30%1. Several studies have shown an independent association between stroke-
associated infections (SAIs) and poor functional outcome, in particular, poststroke 
pneumonia as one of the primary risk factors of death after IS2, 3. The diagnosis of SAI is still 
challenging. Inflammatory markers, as well as clinical and radiological signs often occur after 
the onset of infection with a delay and therefore antibiotic treatment may be initiated also with 
a delay4. However, prophylactic antibiotic treatment in patients did not improve outcome5, 6. 
Consequently accurate and simply available predictive markers for better risk stratification and 
therapy guidance are needed. Several promising candidate blood biomarkers have been 
described recently to be independently associated with SAI4, 7. In a previous pilot study, an 
omics result- guided discovery approach, we could identify SAA (serum amyloid A; 1/2) as a 
potential prognostic biomarker of infection8. In the present study, we aimed to address the value 
of SAA in the prediction of SAI as compared with established inflammatory biomarkers in a 
derivation cohort within 72 hours after stroke onset (study A). Subsequently, we performed a 
more extensive validation study (study B) of the same marker measured at an earlier time-point, 
to determine the incremental value of this marker over other known clinical markers for the 
prediction of SAI.  
2. Methods 
The data that support the findings of this study are available from the corresponding author 
upon reasonable request. 
2.1 Ethics Statement 
The studies (https://www.clinicaltrials.gov; Unique identifier: NCT00390962; PR[AG]157-





approved by the local ethics committees. All patients or their welfare guardians provided 
written informed consent for the collection of data, blood samples, and subsequent analyses.  
 
2.2 Study Designs and Cohort Description 
To evaluate and validate SAA to predict an infection after stroke, post hoc analysis of 2 
separated prospective cohort studies was performed in 2 independent neurology departments. 
For the derivation study (study A), patient eligibility was published previously4. Briefly, 
patients with an acute IS were consecutively enrolled at the University Hospital of Basel, within 
72 hours of symptom onset. In the following validation set (study B), patients with IS were included 
within the first 6 hours after symptom onset, at the emergency department of the Vall d’Hebron 
University Hospital as published previously9. According to the World Health Organization 
criteria, acute IS was defined as an acute focal neurological deficit lasting >24 hours with no sign 
of intracranial hemorrhage on cerebral imaging10. Exclusion criteria in both studies were 
patients with hemorrhagic stroke, TIA and mimicking conditions, and missing informed 
consent. Furthermore, patients with history of and clinical signs of infection on admission or 
14 days before stroke onset were not eligible. All patients received a blood and urine test as 
well as clinical examinations, at admission. Imaging examinations have been done at each clinical 
suspicion of any infection at admission. In both studies, mechanical ventilation was not an 
exclusion criterion. Comorbidities (including chronic inflammatory disease, cancer and renal 
impairment) were assessed by the modified Charlson Comorbidity Index11. A small number of 
patients received anti-inflammatory medication such as corticosteroids (n=11), but only 2 of 
them had an infection. Stroke etiology was defined according to the Trial of Org 10172 in Acute 
Stroke Treatment classification12. Stroke severity was assessed with the National Institutes of 
Health Stroke Scale (NIHSS)13. Supplementary, in study A, a subgroup of patients underwent 
magnetic resonance imaging, and assessment of lesion size was performed (n=135)14. The lesion 
size was calculated by experienced raters using a semiquantitative method as described15, where 
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lesions were categorized into 3 size classes (small lesion, <10 cm3; medium lesion, 10–100 cm3; 
large lesion, >100 cm3)16. In study B, trained nurses assessed dysphagia preferably within the 
first 24 hours after stroke onset, with the volume-viscosity swallow test. 
 
2.3 Follow-Up and Outcome Measure 
Primary outcome measure for this study was presence and time point of any poststroke infection 
throughout hospitalization. More precisely the timeline of observation was defined as the time 
from stroke onset for up to 5 days following the stroke for study A, and up to 7 days for study 
B. Infections were defined according to the US Centers for Disease Control and Prevention 
criteria 1988 to 2008 17 for study A and the updated version 2008 to until now 18 for study B (at 
the time of enrollment for study A the updated Centers for Disease Control and Prevention 
criteria were not available). For both classification systems, blood biomarkers such as CRP or 
PCT are not required for diagnosis of infection. 
The only difference between the older and new criteria is that radiological confirmation was 
mandatory to diagnose a pneumonia. For this study, all patients with any infection containing 
either respiratory tract infection, urinary tract infections, and other types of infections were 
included.18 The treating physician diagnosed the infection during the hospitalization, according 
to the criteria mentioned above. A post-hoc validation was done using charts. Treating 
physicians were blinded to biomarker levels regarding the primary diagnosis, as well as the 
secondary validation. The onset of clinical symptoms led to further investigations and resulted 
in the diagnosis of infection. The time point of the diagnosis was referred to the beginning of 
antibiotic treatment.  
 
2.4 Biomarker Measurement 





Derivation study A: Blood samples were collected within 72 hours from symptom onset, 
including CRP, PCT, white blood cell count and SAA.  
Validation Study B: Single blood sample was collected within 6 hours from symptom onset, 
including only SAA. In study B, conversely to study A, CRP, PCT, white blood cell, and 
monocytes were not measured.  
SAA Measurement for Both Cohorts: After centrifugation during 15 minutes at 1500g at 4 °C, 
serum was obtained and stored at −80 °C until analysis. The Meso Scale Discovery Vascular 
Injury Panel-I ECL assay was used to determine the levels of SAA1/2, as per manufacturer’s 
instructions (Meso Scale Discovery, Gaithersburg, MD). Dilution of 1:1000 was applied to 
each serum sample. Electrochemiluminescence detection system using multiarray technology 
(SECTOR Imager 2400, Meso Scale Discovery) was used to determine analyte concentrations. 
SAA determinations were performed blinded to clinical data. The coefficient of variation of 
the assay between duplicates was below 15%. 
 
2.5 Statistical Analysis 
Continuous variables were expressed as medians (interquartile range [IQR]) and categorical 
variables as counts (percentages). To test for normality, Shapiro-Wilk test was used. To achieve 
normality biomarker data were log-transformed. Pearson χ2 test was used to compare 
categorical variables. Two-group comparison of continuous baseline data was performed by 
the Mann-Whitney U test.  
To investigate the association of SAA with SAI, we calculated logistic regression models. 
Univariate analysis of infection was performed including variables that were significant in the 
derivation or validation cohort (P<0.05), and a first multivariate logistic regression model was 
constructed (model 1). Lesion size was not included in the whole model to avoid bias because 
in >50% of patients magnetic resonance imaging data were missing. Also, microangiopathic 
stroke was not included in the whole model, because there were no patients in the validation 
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cohort with infection and microangiopathic stroke. The nested model was the clinical model 
without the biomarker SAA, and the whole model included all predictors identified by the 
univariate regression analysis including the biomarker SAA. Additionally, to assess the 
independent association of SAA over additional laboratory predictors of infection collected 
just in one cohort (A), model 1 was further adjusted by conventional markers of infection (white 
blood cell, CRP, and PCT) in the derivation cohort (model 2) and by dysphagia (model 3). 
Furthermore, the association of SAA and lesion size was assessed by a binary regression model 
in a subgroup analysis of cohort A, where magnetic resonance imaging was performed (n=135; 
47.7%). Receiver operating characteristic (ROC) curves along with the area under the ROC 
curve as an overall discriminatory measure were calculated. The likelihood ratio test was used 
to test the goodness-of-fit of the whole model versus the nested model. The net reclassification 
improvement (NRI) has been proposed to evaluate prognostic biomarkers19 
 
3. Results 
3.1 Baseline Data 
Derivation Study A: Of 283 patients with acute IS, 60 (21.2%) developed an infection after 
onset of stroke during hospitalization. Twenty (7.1%) patients experienced any respiratory tract 
infection including pneumonia, 21 (7.4%) patients had urinary tract infections, and 19 (6.7%) 
patients had other infections (unknown, 1; sepsis, 11; phlebitis, 3; gastro- enteritis, 1, erysipel: 





7). The median age of the study cohort was 75 (IQR, 63–82) years, and 41% were women. 
Patient characteristics stratified by infected versus noninfected are summarized in Table 1. 
Validation Study B: In the present study, 367 patients with acute IS were included; 111 
(30.2%) of them developed an infection during hospital stay. Any infection of the respiratory 
tract occurred in 83 (22.6%) patients, including pneumonia (10.6%) and bronchitis (12%). 
Eighteen (5%) patients had urinary tract infections, and 22 (6%) had other infections. The 
median time of occurrence of any infection was 2 days after stroke (IQR 1-5). Patient 
characteristics stratified by infected versus noninfected are summarized in Table 1. 
 
3.2 Prediction of poststroke Infection during Hospitalization  
Derivation Study A: Patients with a higher SAA level (on day 0) were more prone to develop 
an infection (17 [IQR, 5–76] versus 5 [IQR, 3–13] µg/mL; P<0.001; Table 1). Patient’s 
characteristics stratified by infection are shown in able 1. SAA was an independent predictor of 
poststroke infection when adjusted by these clinical variables (odds ratio [OR], 1.44 [95% CI, 
1.16–1.79]; P=0.001; Table 2, model 1), and it contributed to an improved discriminatory 
accuracy of the whole multiple logistic regression model (area under the ROC curve change, 
from 0.76 [0.69–0.83] to 0.79 [0.72–0.86]; P<0.001; Table 3, model 1). The combination of 
SAA with the regression model also led to an increase in the continuous NRI of 46.9% (0.133–
0.674). When the model was further adjusted by already known inflammatory markers such as 
white blood cell, CRP, and PCT, SAA remained as an independent predictor of post- stroke 
infection (OR, 1.45 [1.03–2.05]; P=0.034) and increased the NRI by 33.6% (−0.078 to 0.812; 
Table 2, model 2). In a subgroup analysis of patients with available lesion size (n=135; 47.7%), 
no change in the predictive value of SAA was observed (OR, 1.51 [1.13–2.01]; P=0.005; not 
shown in a table). An SAA cutoff level at 4.0 µg/mL gave a sensitivity of 81% and a 
specificity of 44.5% for infection during hospitalization.  
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Validation Study B: Compared with the derivation study, the validation study revealed similar 
results with higher SAA levels predicting the development of an infection (10.4 [5.3–55.5] 
versus 7.2 [3.7–18.7] µg/mL; P=0.0056; Table 1). The association could be shown even earlier, 
within 6 hours of stroke symptom onset. Patient’s characteristics of the validation cohort were 
comparable to those of the derivation cohort. Patients with dysphagia had a higher risk for an 
infection (Table 1). The same logistic regression model (model 1) was evaluated in this 
validation cohort, and again SAA was independently associated with infection (OR, 1.52 [1.05–
2.22]; P=0.028; Table 2, model 1). The improvement of the clinical model was statistically 
significant (area under the ROC curve change, from 0.75 [0.70– 0.81] to 0.76 [0.71–0.82]; 
P=0.038; Table 3, model 1).  
 
4. Discussion  
There is need for an accurate and simply available biomarker permitting early prediction of the 
development of infections after stroke, not only to prevent the development of infections but 
also for better therapy guidance. In a recently performed pilot study, SAA protein 1/2 was 
discovered as an early predictor of poststroke infection (SAI).8 In the present study, we verified 
and validated SAA as a marker of SAI, in 2 independent cohorts of stroke patients, therefore, 
confirming and expanding the results of the previous discovery study. Due to the larger sample 
size of the current studies, adjustments for predictive factors were conceivable. Moreover the 
incremental value beyond demographic and inflammatory risk factors was evaluated using 
different statistical methods. 
In fact, no biomarker has demonstrated usefulness neither in SAI diagnosis nor for its 
prediction, as reviewed by Smith et al20. The blood biomarker SAA is an acute-phase protein, 
which is upregulated by a variety of inflammatory stimuli21. In healthy individuals, SAA 





concentration can rise to 1 mg/mL or even higher23. The function of SAA is still not well 
understood. It is known to have immunomodulatory activity24, 25 and to be the only molecule 
that displays sensitivity and response speed (within hours) similar or even faster to those of 
CRP26. This is coherent with our observation. SAA levels measured on admission (even within 
6 hours after stroke symptom onset) were significant predictors of any infection after stroke 
onset, before clinical signs of infection occurred and diagnostic work-up was initiated. In fact, 
SAA was an independent predictor of SAI and gave additional predictive value over clinical 
variables even when a powerful covariate like dysphagia was included in the model. Of note, 
SAA in comparison to dysphagia is an ultra-early predictor, allowing for risk stratification even 
before dysphagia can reliably be assessed. Moreover, this ultra-early prediction was not 
observed for CRP27. After adjusting for several predictive factors including inflammatory 
markers and severity of stroke, SAA remained independently associated with SAI suggesting 
an incremental prognostic value beyond these traditional risk factors. This incremental value 
was modest but significant shown by the improvement in discrimination when adding SAA to 
the best clinical model.  
In a recently published proteomic discovery study, SAA was identified as a promising predictor 
marker of patients at risk of poststroke infection4, 8, 27. In a small (n=60) study, the highest SAA 
levels were observed between days 1 and 3 in stroke patients with infection compared with 
stroke patients without an infection28. study including 81 patients with subarachnoid 
hemorrhage, SAA levels were significantly higher in 54 patients who developed an infection in 
the course of their hospital stay than in 27 patients who did not29. In our study we could confirm 
the results of these pilot studies.  
As an acute-phase inflammatory mediator, we can hypothesize that an early and severe 
inflammatory response in acute stroke, expressed by increased levels of SAA, might act as a 
predictor of the further development of SAI. Local inflammation is a part of the reactions after 
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stroke, and microglia activation occurs within hours after the ischemic event30. This local 
inflammatory response is rapidly extended to the peripheral circulation by the release of 
proinflammatory cytokines, which start the systemic inflammatory response by activating 
peripheral proteins acting as acute-phase reactants, such as SAA 31. The amount of this 
inflammatory response has been related with a more severe immunodepression in the following 
days, conferring a high vulnerability for SAI32, 33. Therefore, our study supports the role of an 
early inflammatory marker, such as SAA, as a predictor of SAI. However, the precise 
mechanism underlying this association remains to be explored.  
Given the high sensitivity, but lower specificity in a clinical setting where many clinicians start 
antibiotic treatment upon potentially misleading unspecific symptoms such as fever, the marker 
might be best used as “rule out” marker and as such it can help to avoid unnecessary antibiotic 
treatment in some patients with no bacterial infection, while still having a low risk of false 
negative results.  
This seems particularly important regarding the selection of stroke patients for antibiotic 
treatment where empirical antibiotic prophylaxis is discouraged by current guidelines34. The 
combination of clinical variables as well as a panel of serum markers reflecting different 
pathways of the immunological and inflammatory response after stroke, such as SAA, IL-6, or 
classical markers such as CRP, might help to guide antibiotic treatment35.  
This study has limitations: First, different time-ranges for the measurements of SAA were used, 
so that the direct comparison of SAA between the studies was not possible. However, the first 
study was a proof of concept study to assess the magnitude of association in a wider time range 
and the second study was chosen to assess whether this association remained even within the 
very first hours after stroke where risk stratification should be ideally done to prevent infections, 
given that most of them occur within the first 48-72 hours after stroke. Second, no follow-up 





misclassification could have occurred. However, this potential misclassification would have led 
to a bias towards the null hypothesis and thus would rather lead to an underestimation of the 
predictive value of SAA. Third, since not all patients underwent an MRI we could not adjust 
for lesion size in all patients, which may contribute to infection prediction. In a subgroup 
analysis of patients with available lesion size (n=135) there was however no change in the 
predictive value suggesting no major confounding of the predictive value by lesion size. Fourth, 
as only patients with infections in the previous 14 days were excluded from the present study, 
we could not explore whether an infection before 14 days of stroke onset might have been 
responsible elevated SAA levels, as has been studied by Syrjänen et al36. Finally, although we 
adjusted for multiple potential confounders such as age, NIHSS score, hypertension, atrial 
fibrillation, dysphagia in one cohort, residual-confounding effects cannot be excluded.  
In conclusion, among a total of 650 ischemic stroke patients, serum amyloid A measured at 
admission is a novel independent predictor of infection after stroke. SAA improved the 
prediction model of patients who developed any infection. In the future, if validated in a larger 
prospective cohort, SAA could be helpful for closely monitoring a subgroup of patients that 
should be further investigated in radiological or laboratory test in order to prevent the 
development of infection. SAA may facilitate the identification of patients who will not develop 
an infection in order to avoid unnecessary antibiotic treatment.  
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Table 1   
Patient Characteristics Stratified by Infectious Event  
 Derivation Study A  Validation Study B 
 Total No infection  Infection P-Value  Total No infection  Infection  P-Value 
N (%) 283  223 (79) 60 (21)   367  256 (70) 111 (30)  
Demographic data         
Age, y, median (IQR) 75 (63-82) 75 (61-82) 79 (68-83) 0.12  
79 (67-
84) 
77 (65-83) 82 (73-86) <0.0001 
Female sex, n (%) 115 (41) 82 (37) 33 (55) 0.012  192 (52) 136 (53) 56 (51) 0.651 
Medical history, n (%) *          
Hypertension 213 (75) 159 (71) 54 (90) 0.007  264 (72) 175 (68) 89 (80) 0.039 
Atrial fibrillation 57 (20) 38 (17) 19 (32) 0.018  151 (41) 88 (34) 63 (57) <0.0001 
Smoking 104 (37) 80 (36) 24 (40) 0.58  78 (21) 61 (24) 17 (15) 0.099 
Diabetes mellitus 54 (19) 42 (19) 12 (20) 0.45  99 (27) 67 (26) 32 (29) 0.610 
Coronary heart disease 61 (22) 50 (22) 11 (18) 0.76  67 (18) 43 (17) 24 (22) 0.304 
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Dyslipidaemia 73 (26) 59 (26) 14 (23) 0.29  178 (49) 122 (48) 56 (51) 0.572 
Dysphagia NA NA NA NA  63 (17) 22 (9) 41 (37) <0.0001 
Thrombolysis and/or 
endovascular treatment 
55 (19) 34 (15) 21 (35) 0.002  231 (63) 154 (60) 77 (69) 0.058 
Modified Charlson Index, 
median (IQR) 
1 (0-2) 1 (0-2) 1 (0-2) 0.100  NA NA NA NA 
Clinical data, median (IQR)         
Baseline NIHSS (points) 5 (2-10) 4 (2-8) 10 (5-17) <0.0001  
10 (6-
17) 
9 (5-14) 16 (9-20) <0.0001 
Laboratory values, median (IQR)         
White blood count (g/l) 8.2 (7-10) 7.8 (6-9) 9.6 (8-11) <0.0001  NA NA NA NA 
Monocytes (%) 0.4 (0.3-0.5) 0.4 (0.3-0.5) 0.4 (0.3-0.5) 0.27  NA NA NA NA 








0.0047  NA NA NA NA 
 
 








Stroke etiology (TOAST) , n (%)*   
Large vessel stroke 54 (19) 43 (19) 11 (18) 1.00  51 (14) 35 (14) 16 (14) 0.696 
Cardioembolic stroke 97 (34) 68 (31) 29 (48) 0.02  166 (45) 106 (41) 60 (54) 0.063 
Microangiopathic stroke 49 (17) 43 (19) 6 (10) 0.22  27 (7) 27 (11) 0 NA 
Other known 13 (5) 11 (5) 2 (3) 0.80  11 (3) 8 (3) 3 (3) 1.00 
Cryptogenic stroke 69 (24) 57 (26) 12 (20) 0.53  112 (31) 80 (31) 32 (29) 0.601 
Abbreviations: y = years, IQR = interquartile range; NIHSS = National Institutes of Health Stroke Scale; SAA = Serum Amyloid A; CRP = C-
reactive protein; WBC = white blood cells; PCT = Procalcitonin; TOAST = Trial of Org 10172 in Acute Stroke Treatment; NA = not applicable.  
Statistics: Values are median (IQR) or number (percent). The P-Values were assessed using the Mann-Whitney U Test and Pearson chi-squared. P-
Values <0.05 were considered statistically significant.  
*Because of rounding, percentages may not total 100.  






Table 2  
Multivariable Logistic Regression Model For The Occurrence Of Any Post Stroke Infection 
  Derivation Study A  Validation Study B 
Models Predictors Odds Ratioa  95% - CI P-Value  Odds Ratioa  95% - CI P-Value 
Model 1 
Log_SAA* 1.44 1.16 – 1.79 0.001  1.52 1.05 – 2.22 0.028 
Age 1.01 0.98 – 1.05 0.351  1.03 1.01– 1.05 0.016 
Female sex 1.80 0.88 – 3.69 0.110  0.59 0.35 – 1.01 0.054 
Baseline NIHSS 1.05 1.00 – 1.10 0.068  1.12 1.07 – 1.17 <0.0001 
Art. Hypertension 3.42 1.24 – 9.49 0.018  1.76 0.94 – 3.29 0.075 
Atrial fibrillation 1.02 0.38 – 2.74 0.963  2.07 0.94 – 4.63 0.076 
Cardioembolic stroke 1.31 0.60 – 2.93 0.504  0.66 0.30 – 1.46 0.308 
 
Thrombolysis and/or endovascular 
treatment 
2.79 1.18 – 6.62 0.020  1.27 0.72 – 2.24 0.409 
Pseudo-R2    0.1828    0.1596 
Model 2 Log_SAA* 1.45 1.03 – 2.05 0.034  NA NA NA 
 
 
Age 1.03 0.99 – 1.06 0.113  NA NA NA 
Female sex 2.01 0.92 – 4.40 0.079  NA NA NA 
Baseline NIHSS 1.05 0.99 – 1.10 0.084  NA NA NA 
Art. Hypertension 2.73 0.96 – 7.74 0.060  NA NA NA 
Atrial fibrillation 0.74 0.26 – 2.15 0.583  NA NA NA 
Cardioembolic stroke 1.56 0.67 – 3.63 0.301  NA NA NA 
Thrombolysis and/or endovascular 
treatment 
3.73 1.51 – 9.21 0.004  NA NA NA 
Log_WBC* 2.93 0.93 – 9.23 0.066  NA NA NA 
Log_CRP * 0.77 0.44 – 1.33 0.350  NA NA NA 
Log_PCT * 1.62 0.99 – 2.67 0.057  NA NA NA 
Pseudo-R2    0.2303    NA 
Model 3 
Log_SAA* NA NA NA  1.66 1.02 – 2.70 0.040 
Age NA NA NA  1.01 0.98 – 1.04 0.389 
Female sex NA NA NA  0.53 0.25 – 1.11 0.093 
Baseline NIHSS NA NA NA  1.15 1.08 – 1.23 <0.0001 
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Art. Hypertension NA NA NA  2.85 1.18 – 6.91 0.020 
Atrial fibrillation NA NA NA  1.07 0.36 – 3.17 0.901 
Cardioembolic stroke NA NA NA  0.81 0.29 – 1.61 0.389 
Thrombolysis and/or endovascular 
treatment 
NA NA NA  0.69 0.29 – 1.61 0.389 
Dysphagia  NA NA NA  5.06 2.46 – 10.39 <0.0001 
Pseudo-R2    NA    0.2412 
Abbreviations: SAA = serum amyloid A; NIHSS = National Institutes of Health Stroke Scale; CRP = C-reactive protein; WBC = white blood cells; 
PCT = Procalcitonin; CI = confidence interval; NA = not applicable. 
*Odds ratio refers to a 1-unit increase in the explanatory variable and to any 10-fold increase in SAA, WBC; CRP and WBC (log transformed with 









Table 3  
AUC To Predict An Infectious Event During Hospitalization 
 Derivation Study A  Validation Study 
        
Predictors AUC 95% - CI Likelihood Ratio test§ AUC 95% - CI Likelihood Ratio test§ 
Model 1* 0.76 0.69 – 0.83 NA  0.75 0.70 – 0.81 NA 
Model 1* and SAA 0.79 0.72 – 0.86 <0.0001  0.76 0.71 – 0.82 0.038 
Model 2† 0.80 0.73 – 0.87 NA  NA NA NA 
Model 2† and SAA 0.81 0.74 – 0.88 0.0314  NA NA NA 
Model 3‡  NA NA NA  0.81 0.74 – 0.87 NA 
Model 3‡ and SAA NA NA NA  0.81 0.76 – 0.88 0.0393 
Abbreviations: SAA = serum amyloid A; NIHSS = National Institutes of Health Stroke Scale; CRP = C-reactive protein; WBC = white blood cells; 
PCT = Procalcitonin; NA = not applicable; AUC = Area under the curve. 
*Model 1, (age, female sex, baseline NIHSS, hypertension, atrial fibrillation, cardioembolic stroke, Thrombolysis and/or endovascular treatment) 
multivariate logistic regression model presented in table 2. 
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†Model 2, (age, female sex, baseline NIHSS, hypertension, atrial fibrillation, cardioembolic stroke, Thrombolysis and/or endovascular treatment, 
WBC, CRP, PCT), multivariate logistic regression model presented in table 2. 
‡ Model 3, (age, female sex, baseline NIHSS, hypertension, atrial fibrillation, cardioembolic stroke, Thrombolysis and/or endovascular treatment, 
Dysphagia), multivariate logistic regression model presented in table 2. 
§ The likelihood ratio test was used to test the goodness-of-fit of the whole model vs the nested model. 
 
 
